Fig. 7: Topical administration of rmIL-9 caused barrier disruption of corneal and conjunctival epithelium in ST2−/− mice.
From: IL-33/ST2/IL-9/IL-9R signaling disrupts ocular surface barrier in allergic inflammation
The ocular surface of ST2−/− mice was topically administrated by rmIL-9 at 50 ng/ml, three times per day for 3 days, with PBS eyedrop as control. a OGD staining in the cornea from ST2−/− mice, which were untreated, treated with PBS or rmIL-9. ZO-1, claudin 1, occludin, and E-cadherin in the corneal (b) and conjunctival (c) epithelia of ST2−/− mice treated with rmIL-9 or PBS control were detected by whole-mount IF staining with quantification (d). Results shown are the mean ± SD (n = 5). *P < 0.05, **P < 0.01, ***P < 0.001, compared with PBS controls. Bar: 20 μm.
